Furthermore, RMRP inhibition can attenuate lipid accumulation and prevent NAFLD progression by targeting the miR-206/PTPN1 axis and down-regulating the miR-206/PTPN1-SREBP1C and PTPN1-PP2A-SP1-SREBP1C signaling pathways in both rat models of NAFLD and FFA-treated AML-12 cells. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.